Skip to main content

Manhattan biotech startup to commercialize MD Anderson research

A biotech startup that's developing a drug to slow the effects of neurodegenerative disease and brain injury will announce plans today to plant its flag in Manhattan. The company, Magnolia... To view the full story, click the title link.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.